Clinical trial · Observational
Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
NCT02408536CI-TRIAL-00064977MITO 22unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low-grade Serous Ovarian Carcinoma | — | UNRESOLVED | — |
| Recurrent Invasive Borderline Serous Ovarian Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Single cohort
- description
- Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
Primary outcomes (6)
- measure
- risk of recurrence in patients with low-grade serous ovarian carcinoma
- timeFrame
- two years
- measure
- number of patients with objective tumor response after receiving chemotherapy
- timeFrame
- 6 months
- measure
- number of patients with objective tumor response after receiving hormone therapy
- timeFrame
- 6 months
- measure
- number of patients with objective tumor response after receiving combination hormonal and chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis low-grade serous ovarian carcinoma * OR invasive recurrence after surgical resection of borderline serous ovarian carcinoma * Availability of archival tumor specimen (paraffin embedded block) for central analysis and evaluation for mutations * Age \> 18 years * Signed informed consent Exclusion Criteria: * High-grade serous, mucinous, endometrioid, or any other non-low-grade serous ovarian carcinoma * Unavailability of archival tumor specimen
References
Publications (1)
- DERIVEDMusacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferrau F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22. PMID 35869143